Analysis of immune status in autoimmune diseases treated with Biologics

Analysis of immune status in autoimmune diseases treated with Biologics - Analysis of immune status in autoimmune diseases treated with Biologics

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012916

Enrollment

Registered

2014-01-21

Start date

2014-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune diseases

Interventions

Biologics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Males and Females diagnosed rheumatoid arthritis must -be more than 20 years old -be informed and will give written informed consent

Exclusion criteria

Exclusion criteria: -Complicated with active infectious disease -The Petients who the doctors in charge consider should not enter this study

Design outcomes

Primary

Measure	Time frame
Biomarkers in sera and the surface markers on peripheral blood cells mRNA of disease related molecules were analyzed by ELISA,FACS and RT-PCR in autoimmune diseases treated with biologics	—

Secondary

Measure	Time frame
To evaluate efficacy of Biologics -clinical assessment;DAS 28,High sensitivity C-reactive protein etc.	—

Countries

Japan

Contacts

Public ContactAtsushi Ogata

Osaka University Department of Respiratory Medicine, Allergy and Rheumatic Disease

ogata@imed3.med.osaka-u.ac.jp06-6879-3833

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026